Potential Role of Exosomes in Cancer Metastasis

Wenjuan Tian,1,2 Shanshan Liu,1,2 and Burong Li1

1Department of Clinical Laboratory, Second Affiliated Hospital, Xi’an Jiaotong University, Xi’an, Shaanxi, 710004, China
2School of Medicine, Xi’an Jiaotong University, Xi’an, Shaanxi, 710061, China

Correspondence should be addressed to Burong Li; liburong@163.com

Received 5 February 2019; Revised 2 April 2019; Accepted 24 April 2019; Published 2 July 2019

Guest Editor: Shi-Cong Tao

Copyright © 2019 Wenjuan Tian et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

High cancer mortality is attributed to metastasis to a large extent. However, cancer metastasis remains devoid of dynamic monitoring and early prevention in terms of current advances in diagnostic means and therapeutic modalities. Meanwhile, studies have shown that reciprocal crosstalk among cells via exosomes plays a critical role in maintaining normal physiological state or triggering disease progression, including cancer metastasis. Therefore, in this review, we focus on the latest literature (primarily from 2018) to summarize action mechanisms and experimental studies of exosomes in cancer metastasis and put forward some problems as well as new outlooks of these studies.

1. Introduction

Cancer is responsible for approximately 1 out of every 6 deaths and is the second-leading cause of death (following cardiovascular diseases) worldwide [1]. Meanwhile, metastases as well as their treatment consequences are the leading causes for cancer death [2]. Cancer statistics in 2019 from the American Cancer Society show the following estimates: the largest number of cancer deaths will be attributed to lung, prostate, and colorectal cancer in men. In women, lung, breast, and colorectal cancer will be largest. Moreover, the mortality of lung cancer will account for 25% of cancer deaths in 2019 [3].

Despite advances in cancer therapy, including chemoradiotherapy, immunotherapy, and molecular targeted treatment, there has yet to be satisfactory clinical outcome for patients within cancer metastasis [2, 4]. In addition, most new therapeutic strategies were developed according to their anticancer activity against tumorigenesis and primary growth, rather than their antimetastatic activity. Preclinical evidence and further clinical therapy applications of agents with antimetastatic activity are still lacking [4]. Therefore, it will be very important to develop specifically antimetastatic drug for clinical application. This will require researchers to focus their efforts on the mechanisms of cancer metastasis.

Cancer metastasis refers to the process of primary tumor cells arriving to other sites of the body, proliferating there and finally forming new tumors. It includes four main stages: intravasation (from primary tumor sites to blood vessels), extravasation (from blood circulation to future metastasis sites), tumor latency, and formation of micrometastasis and macrometastasis. The process of metastasis is modulated by epithelial-mesenchymal transition (EMT) and the reverse (MET), extracellular matrix (ECM) remodeling, activity of immune system, characteristics alteration of tumor cells, reprogramming of microenvironment cells (fibroblasts, macrophages, endothelial cells, etc.), and recruitment of bone marrow-derived cells (BMDC), such as mesenchymal stem cells (MSC) [5, 6]. In addition, the organ specificity of metastasis has gradually been unveiled by the “seed” and “soil” theory of Paget and studies of Isaiah Fidler [5]. Another intriguing finding is that organs targeted for metastasis can be altered to become suitable for tumor colonization before the arrival of cancer cells, that is, by formation of a premetastatic niche [6, 7].

Further studies have shown that exosomes play a vital role in cancer metastasis, namely, contributing in forming the premetastatic niche, influencing tumor cells and microenvironment, and determining specific organotropism metastasis [2, 4, 7]. Exosomes are formed by the inward budding of early endosomes to produce multivesicular endosomes and their fusion with cell plasma membranes [8]. They belong to the so-called extracellular vesicles (EVs) which generally include three types: apoptotic bodies, cellular microparticles
2. Exosomes in Cancer Metastasis

Exosomes, serving as a cell complement, function mainly via monitoring the specific organotropism of primary tumor cells, and altering the microenvironment of targeted organs and primary tumor organs. They influence the function of tumor cells, and they change the efficacy of chemotherapy, thereby possibly functioning as dynamic monitoring biomarkers and therapeutic targets for cancer metastasis.

2.1. Role of Exosomes in Organ-Specific Targeting. The pioneering study from group of Prof. Layden [16] has demonstrated that exosomal integrins (ITGs) play an important role in organ-specific metastasis and colonization of tumor cells in distant sites. Their main ideas include the following. (i) tumor-derived exosomal ITGs determine the metastatic sites of the primary tumor cells; namely, exosomal ITGα<sub>2</sub>β<sub>1</sub> and -α<sub>5</sub>β<sub>1</sub> are associated with lung metastasis, while ITGα<sub>5</sub>β<sub>3</sub> is associated with liver metastasis, and ITGβ<sub>3</sub> is associated with brain metastasis. (ii) These ITGs mediate the interaction of exosomes and specific resident cells of the targeted organ, namely, lung-tropic tumor-derived exosomes and lung fibroblasts and epithelial cells; liver-tropic tumor-derived exosomes and liver Kupffer cells, brain-tropic tumor-derived exosomes, and brain endothelial cells. (iii) The above interactions depend on exosomal ITGs selectively adhering to the ECM associated with specific resident cells, including laminin of lung microenvironments and fibronectin of liver microenvironments, respectively. (vi) Exosomal ITGs regulate the function of targeted cells by activating proto-oncogene tyrosine-protein kinase Src (Src) and increasing the expression of S100 (a family of genes whose symbols use the S100 prefix) gene to promote migration and inflammation. (v) Exosomal ITG content is positively associated with cancer progression. Another report from the above group has shown that pancreatic ductal adenocarcinomas (PDAC) cells-derived exosomes play a part in determining liver-tropic metastasis. These exosomes transfer migration inhibitory factor (MIF) to Kupffer cells. Thus Kupffer cells secret more transforming growth factor beta (TGF-β) and promote the production of fibronectin by hepatic stellate cells. Subsequently, the accumulation of fibronectin is advantageous in recruiting bone marrow-derived macrophages and forming the premetastatic niche [17]. Moreover, exosomal ITGα<sub>5</sub>β<sub>3</sub> is also correlated with brain-tropic metastasis, while exosomal ITGα<sub>4</sub>β<sub>1</sub> and -α<sub>5</sub>β<sub>3</sub> promote the metastasis to bone, and exosomal ITGβ<sub>4</sub> is related to lymph node (LN) metastasis [18]. Figure 1 summarizes the above content.

2.2. Influence of Exosomes in Altering the Tumor Microenvironment. Tumor cells-derived and microenvironment cells-derived exosomes modify the microenvironment of the primary tumor and make targeted organ suitable for tumor progression (Table 1).

2.2.1. Tumor Cells-Derived Exosomes. The tumor cells-derived exosomes transfer some crucial miRNAs, lncRNAs, and proteins to the cancer microenvironment cells, mainly containing epithelial cells, macrophages, endothelial cells, and fibroblasts. This contributes to inflammatory cell infiltration, angiogenesis, obtaining of tumor-associated cell phenotypes, and tumor innervation.

The binding of RNA to toll-like receptor (TLR) of epithelial cells or macrophages can induce tumor microenvironment inflammatory phenotypes. Liu et al. [19] have shown that exosomal small nuclear RNAs (snRNAs) of Lewis lung carcinoma (LLC) or B16/F10 melanoma cells activate TLR3 of alveolar epithelial cells and then promote chemokine release which recruits neutrophils to the lung microenvironment. Furthermore, these exosomal RNAs promote the metastasis progression by influencing the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-KB) and mitogen-activated protein kinase (MAPK) pathways. In addition, it is reported that colorectal cancer (CRC) cells-derived exosomal miR-21 activates TLR7 in cytoplasm of liver macrophages. This activation results in proinflammatory phenotype transformation of macrophages with increasing expression of interleukin (IL)-6, S100 calcium-binding protein A (S100A), and matrix metalloproteinases (MMPs). Meanwhile, by a positive feedback, the above upregulated IL-6 can stimulate the expression of miR-21 mediated by signal transducer and activator of transcription 3 (STAT3) [20, 21].

The crosstalk between cancer cells and endothelial cells facilitates angiogenesis. Epithelial ovarian cancer (EOC) cells-derived exosomes enhance proangiogenic properties of human umbilical vein endothelial cells (HUVECs) via metastasis-associated lung adenocarcinoma transcript 1 (MALATI) trafficking which may stimulate the expression of vascular endothelial growth factor (VEGF)-A, VEGF-D, epithelial-derived neutrophil-activating protein 78 (ENA-78), placental growth factor (PlGF), IL-8, angioigenin, basic fibroblast growth factor (bFGF), and leptin in HUVECs [22]. In addition, exosomal miR-25-3p from CRC cells can be internalized by HUVECs, which gives rise to decreasing expression of Krüppel-like factor 2 (KLF2) and KLF4 with the respective functions of inhibiting angiogenesis and maintaining the integrity of endothelial barrier [23]. Pessolano et al. have studied the role of exosomal annexin A1 (ANXA1) in pancreatic cancer via the MIA PaCa-2 model and knock-out technology of clustered regularly interspaced short palindromic repeats (CRISPR)-associated protein 9 (CRISPR/Cas9). They have indicated that ANXA1 can elevate exosomes production. Moreover, exosomal ANXA1 can promote migration, invasion, and EMT of pancreatic cancer cells, as well as angiogenesis by
interaction with HUVECs [24]. Tumor released-exosomal miR-221-3p promotes lymphangiogenesis and LN metastasis in cervical squamous cell carcinoma (CSCC) by its transmission to human lymphatic endothelial cells (HLECs), which results in the activation of miR-221-3p-vasohibin-1 (VASH1-) extracellular signal-regulated kinase (ERK)/serine/threonine-protein kinase Akt (AKT) signal axis [25].

Exosomes communicating with fibroblasts also trigger reprogramming of recipient cells into cancer-associated phenotypes. These exosomes released from lung adenocarcinoma cells (LAC) transfer miR-142-3p to lung endothelial cells and fibroblasts, which promotes angiogenesis mediated by inhibiting TGFβRI in endothelial cells and induces fibroblasts tumor-associated phenotypes but may be irrelevant to TGFβ signaling pathway [26]. Wang et al. have demonstrated that exosomal miR-27a from gastric cancer cells are also relevant to malignant transformation of fibroblasts [27].

Exosomes can also increase the nerve distribution of the microenvironment to elevate the malignant degree of tumor cells. Head and neck squamous cell carcinomas (HNSCC) released-exosomal EphrinB1 can induce tumor innervation in the PC12 neuronal model in vitro and the murine model in vivo, and patients with increased tumor innervation are prone to suffer from cancer metastasis [28].

2.2.2. Tumor Associated Microenvironment Cells-Derived Exosomes. Meanwhile, surrounding stromal cells-derived exosomes are also involved in preparing microenvironment amenable for tumor colonization.

EOC-associated macrophages transfer miR-29a-3p and miR-21-5p to CD4+ T cells via exosomes, which synergistically inhibits the activity of STAT3 and causes the imbalance of regulatory T cells (Treg)/helper T cell 17 (Th17). This contributes to form an immune-suppressive microenvironment [29].

Figure 1: Role of exosomes in organ-specific targeting. Pancreatic ductal adenocarcinoma, PDAC.
Table 1: Influence of exosomes in altering the tumor microenvironment.

| Donor cells | Recipient cells | Mechanisms of action | Effects | Ref. |
|-------------|-----------------|----------------------|---------|-----|
| LLC or 16/F10 melanoma cells | Alveolar epithelial cells | | Promote ECM remodeling, the formation of inflammatory tumor microenvironment and pre-metastatic niche | [19] |
| CRC cells | Liver macrophages | | | [20, 21] |

| EOC cells | Umbilical vein endothelial cells (HUVECs) | | Contribute to angiogenesis | [22] |
| CRC cells | Lymphatic endothelial cells (HLECs) | | | [23] |
| Pancreatic cancer cells | | | | [24] |
| CSCC cells | | | | [25] |
| LAC cells | Lung endothelial cells | | | [26] |
| LAC cells | Fibroblasts | | Promote the cancer-associated phenotype transformation of fibroblasts | [26] |
| Gastric cancer cells | Lymphatic endothelial cells (HLECs) | | | [27] |
| HNSCC cells | Neuronal models | | Increase the nerve distribution of tumor microenvironment | [28] |

The role of tumor microenvironment cells-derived exosomes in influencing the function of tumor microenvironment cells.

| EOC-associated macrophages | CD4+ T cells | Form an immune-suppressive microenvironment | [29] |
| MSCs | Tumor stromal cells | Affect angiogenesis, immune response, migration and invasion of tumor | [30, 31] |

Note: Lewis lung carcinoma, LLC; Colorectal cancer, CRC; Epithelial ovarian cancer, EOC; Cervical squamous cell carcinoma, CSCC; Lung adenocarcinoma, LAC; Head and neck squamous cell carcinoma, HNSCC; Mesenchymal stem cell, MSC; Human umbilical vein endothelial cell, HUVEC; Human lymphatic endothelial cell, HLEC; ↑, Upregulated or activated; ↓, Downregulated or inhibited; —, Inhibited.
Table 2: Involvement of exosomes in influencing the function of tumor cells.

| Cancer type | Donor cells | Recipient cells | Study molecule | Signal axis | Effect | Ref. |
|-------------|-------------|----------------|----------------|-------------|--------|------|
| Melanoma    | Tumor cells | Tumor cells    | RAB27A         | Inc-MMP2-2  | Migration and invasion ↑ | [32] |
| Lung cancer | Tumor cells | Tumor cells    | Inc-MMP2-2     | HIF1A→Wnt4-activated β-catenin signaling pathway ↑ | Migration and invasion ↑ | [33] |
| CRC         | Hypoxic tumor cells | Normoxic tumor cells | HIF1A | | Migration and invasion ↑ | [34] |
| PDAC        | Tumor cells | Tumor cells    | miR-222        | miR-222→p27↓ | Proliferation, invasion and migration ↑ | [35] |
| Breast cancer | Tumor cells | Tumor cells    | CAV1           | | Migration and invasion ↑ | [36] |
| Breast cancer | Exosomes from plasma of healthy donor (the exception of study mode) | Tumor cells | surface proteins | surface proteins→FAK signaling pathway ↑ | Adhesive ability and migration ↑ | [37] |

The role of microenvironment cells-derived exosomes in influencing tumor cells

| Cancer type | Donor cells | Recipient cells | Study molecule | Signal axis | Effect | Ref. |
|-------------|-------------|----------------|----------------|-------------|--------|------|
| CRC         | Tumor associated M2 macrophages | Tumor cells | miR-21-5p and miR-155-5p | miR-21-5p and miR-155-5p → BRG1↑ | Migration and invasion ↑ | [38] |
| OSCC        | CAFs        | Tumor cells    | miR-34a-5p     | miR-34a-5p→AXL↓→AKT/GSK-3β/β-catenin signaling pathway ↑ | Proliferation, EMT and metastasis ↑ | [39] |
| HCC         | CSCs        | Tumor cells    | exosomal molecules | exosomal molecules→Bax and p53↑, Bcl2↓; VEGF↑; PI3K, ERK and MMP9↑, TIMP1↓; TGFβ↑ | Tumor progression ↑ | [40] |
|            | BM-MSCs     | Tumor cells    | exosomal molecules | contrary to the above expression changes | Tumor progression ↑ | |

Note: Colorectal cancer, CRC, Pancreatic ductal adenocarcinoma, PDAC; Oral squamous cell carcinoma, OSCC; Cancer-associated fibroblast, CAF; Hepatocellular carcinoma, HCC; Cancer stem cell, CSC; Bone marrow-mesenchymal stem cell, BM-MSC; ↑, Upregulated or activated; ↓, Downregulated or inhibited.

MSCs play dual roles-stimulative or inhibitory in tumor progression by the interaction of MSC-derived exosomes and tumor microenvironment cells, which affects angiogenesis, immune response, migration, and invasion of tumors [30, 31].

2.3. Involvement of Exosomes in Influencing the Functions of Tumor Cells. Tumor cells- and microenvironment cells-derived exosomes commonly act on changing the proliferation, migration, invasion, and further distant metastasis of tumor cells (Table 2).

2.3.1. Tumor Cells-Derived Exosomes. Tumor cells-released exosomes affect activities of tumor cells via autocrine and paracrine processes.

Ras-related protein Rab-27A (RAB27A) is upregulated in melanomas compared with normal skin or nevi and is related to the advanced stage of melanomas for patients. Exosomes enriched with RAB27A can rescue the invasion phenotype of the melanoma cells after the knockdown of RAB27A, which reveals that exosomes promote melanoma metastasis by changing the ability of invasion and motility of surrounding melanoma cells [32]. Exosomal Inc-matrix metalloproteinase 2-2 (Inc-MMP2-2) mediated by TGF-β upregulates the expression of MMP2 in lung cancer cells by its enhancer activity, which leads to increasing migration and invasion of tumor cells via the increasing vascular permeability [33]. Hypoxic CRC cells-derived exosomes promote the migration and invasion of normoxic CRC cells via protein Wnt-4- (Wnt4-) activated β-catenin signaling pathway, and the function depends on the hypoxia-inducible factor 1-alpha (HIF1A) expression of hypoxic cells. Upregulated HIF1A increases Wnt4 expression in hypoxic CRC cells and their released exosomes [34]. In PDAC, exosomal miR-222 transmission to cancer cells is functional to promote proliferation, invasion, and migration through two ways: (i) decreasing cyclin-dependent kinase inhibitor 1B (p27Kip1) (p27) expression levels directly; (ii) activating AKT by inhibition of serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B alpha isoform (PPP2R2A), which increases p27 phosphorylation and cytoplasmic p27 expression coupled with reduced nucleus expression [35]. Breast cancer cells-derived exosomal caveolin-1 (CAV1) can facilitate migration and invasion of cells with knockout of CAV1 in vitro. CAV1 is positively associated with cancer stages, which may suggest that exosomal CAV1 transferred to recipient cells promotes cancer metastasis in vivo [36].
In addition, there is a distinct model for studying exosomes function. When most studies focus on tumor-derived exosomes, Shtam et al. pay attention to exosomes from plasma of healthy donor. They have found that these exosomes can increase adhesive ability of breast cancer cells in vitro and migratory activities in Zebrafish model, which is dependent on the interaction of exosomal surface proteins and breast cancer cells, and the activation of focal adhesion kinase (FAK) signaling pathway [37].

2.3.2. Tumor Associated Microenvironment Cells-Derived Exosomes. When tumor cells-derived exosomes modify diverse tumor associated microenvironment cells, in turn, these cells release exosomes acting on the functions of tumor cells.

For CRC metastasis, exosomes derived from tumor associated M2 macrophage transfer miR-21-5p and miR-155-5p to CRC cells, which results in downregulated expression of transcription activator BRGI (BRGI) and enhanced migration and invasion of cancer cells [38]. In oral squamous cell carcinoma (OSCC), cancer-associated fibroblasts-(CAFs-) secreted exosomes deliver miR-34a-5p to cancer cells. Then miR-34a-5p activates AKT/glycogen synthase kinase-3 beta (GSK-3β)/β-catenin signaling pathway via the inhibition of tyrosine-protein kinase receptor AXL (AXL), which causes increased nuclear location of β-catenin and further upregulated expression of zinc finger transcription factor SNAIL (SNAIL) as well as MMP-2 and MMP-9. This finally plays an essential role in accelerating proliferation, EMT, and metastasis of cancer cells [39]. By the application of diethylnitrosamine- (DEN-) inducing long-term animal models of hepatocellular carcinoma (HCC), Alzahrani et al. have found that hepatic cancer stem cells- (CSCs-) derived exosomes function as protumor factors while bone marrow-mesenchymal stem cells (BM-MSCs) released-exosomes play an inhibitory role in tumor progression. These exosomal molecules influence apoptosis, angiogenesis, metastasis, and invasiveness as well as EMT of tumor cells via altering the expression of targeted molecules. These molecules include apoptosis regulator BAX (Bax), cellular tumor antigen p53 (p53), apoptosis regulator Bcl-2 (Bcl2), VEGF, phosphoinositide 3-kinase (PI3K), extracellular signal-regulated kinase (ERK), MMP9, tissue inhibitor of metalloproteinases 1 (TIMP1), and TGFβ1 [40].

2.4. Influence of Exosomes in Changing the Efficacy of Chemotherapy. Exosomes can transfer resistance to chemotherapy via two different ways (Figure 2): (i) the tumor induces chemotherapy resistance and, reversely, (ii) chemotherapy also promotes drug resistance.

A recent study shows that in hypoxic tumor microenvironment of EOC, tumor associated macrophages- (TAMs-) derived exosomes induce chemotherapy resistance of tumor cells via delivering miR-223 and activating miR-223/ phosphatase and tensin homolog- (PTEN-) PI3K/AKT signaling pathway [50]. In turn, chemotherapy may promote cancer metastasis. Keklikoglou et al. have demonstrated that in the breast cancer model, chemotherapy promotes the formation of lung premetastatic niche by increased release of tumor-derived EVs. These chemotherapy-stimulated EVs function as the prometastatic factor by transferring annexin A6 (ANXA6) to lung endothelial cells and then activating NF-κB signaling pathways, which causes C-C motif chemokine 2 (CCL2) upregulation, lymphocyte antigen 6C positive and C-C chemokine receptor type 2 positive (Ly6C+ CCR2+) monocyte accumulation, and tumor cells colonization in lung [51].

2.5. Exosomes as Potential Biomarkers of Cancer Metastasis. Some studies focus on difference analysis based on different molecular components to select exosomal biomarkers, which sets the stage for in-depth mechanism investigation (Table 3).

2.5.1. Exosomal RNAs. Exosomal miR-140-3p, miR-30d-5p, miR-29b-3p, miR-130b-3p, miR-330-5p, and miR-296-3p are associated with the migration ability of hepatocarcinoma cells by the comparison analysis of exosomal miRNAs profile in fast- and slow-migrating groups of patient-derived liver cells (PDLCs). The migration ability is assessed by the wound closure percentage of wound healing assay [41]. Serum exosomal miRNA-21 and IncRNA activated by tumor growth factor-beta (IncRNA-ATB) levels in HCC patients are positively related to tumor progression [42]. miR-9 and miR-155 levels are higher in metastatic breast cancer-derived exosomes and the two miRNAs downregulate the expression of PTEN and dual specificity protein phosphatase 14 (DUSP14) in recipient cells [43]. In castration-resistant prostate cancer (CRPC), the high level of plasma exosomal miR-1290 and miR-375 is connected with poor prognosis of patients [44]. Moreover, the study of Cannistraci et al. has indicated that the expression of exosomal tyrosine-protein kinase Met (Met)/miR-130b axis in serum is related to the risk that patients with prostate cancer become resistant to castration therapy and suffer from metastasis [45]. In serum and urine of urothelial carcinoma of the bladder (UCB) patients, exosomal protein arginine N-methyltransferase 5 circular RNA (circPRMT5) levels are upregulated and associated with metastasis. The binding of circPRMT5 to miR-30c inhibits the function of miR-30c. Therefore circPRMT5 boosts EMT of UCB cells via increasing expression of SNAIL1 and reducing expression of E-cadherin, the downstream target of SNAIL1 [46].

2.5.2. Exosomal Proteins. Wang et al. have shown that the level of CD82 antigen (CD82) in exosomes is negatively correlated with that in tissue for breast cancer patients, and the content of serum exosomal CD82 is higher in cancer group than that in the benign group and healthy control group. CD82 expression in serum exosomes is also positively correlated with cancer clinical stage. Therefore, there may be a redistribution of CD82 from tissue to serum exosomes, which reflects tumorigenesis and progression of breast cancer [47]. Ohshima K et al. have indicated that exosomal epidermal growth factor receptor pathway sub- strate 8 (Eps8) protein content is higher in metastatic cells-derived exosomes by the comparative proteome analysis of exosomes, which are purified from human pancreatic cancer cell lines with distinct stages [48]. For CRC patients with lung metastasis, studies have revealed that C-X-C chemokine receptor type 7 (CXCR7) and C-X-C motif chemokine ligand
Figure 2: Influence of exosomes in changing the efficacy of chemotherapy. Tumor associated macrophage, TAM; epithelial ovarian cancer, EOC; ↑, upregulated.

12 (CXCL12) expression is significantly higher in metastatic site than in primary lesion, and CXCL12 expression is higher in nontumor lung tissue of patients with CRC than in control lung tissue with benign lesion. In addition, after injection of exosomes isolated from CRC cell line (CT26) into BALB/c female mice, CXCL12 expression is increased in lung tissue before cancer metastasis. Based on the above finding, the authors have stated that CRC cells-derived exosomes elevate CXCL12 expression levels in lung before metastasis [49].

The multidirectional communications of tumor cells and tumor associated microenvironment cells via the trafficking of exosomes facilitate the enhancement of malignant phenotypes of tumor cells, promote the formation of premetastatic niche, and finally exhibit clinically detectable metastasis.

In view of the important involvement of exosomes in cancer metastasis, more in-depth studies of exosomes are expected to shed more light on its biogenesis, release, and relevant functions. However, these exosome results may be questionable, due to the lack of standard isolation and characterization methods. Another disturbing factor is the fact that other EV types are likely interfering with the analysis of exosomes [9]. Indeed, the used methods currently based on size, protein composition, and morphology are not sufficient to completely separate one type of EVs from the others [8]. As is shown in Table S1, the overlap of size range occurs among the three main types of EVs. Moreover, the size range is slightly inconsistent in the literature possibly due to the various cell origin and different isolation methods among
Table 3: Potential exosomal biomarkers of cancer metastasis.

| Potential biomarkers | Comparison analysis | Ref. |
|----------------------|---------------------|------|
| Exosomal RNAs        |                     |      |
| miR-140-3p, miR-30d-5p, miR-29b-3p, miR-130b-3p, miR-330-5p, miR-296-3p | Exosomes derived from fast- and slow-migrating groups of PDLCs | [41] |
| miRNA-21 and IncRNA-ATB | Serum exosomes isolated from patients with different HCC stages | [42] |
| miR-9 and miR-155    | Exosomes derived from breast cells with different metastatic ability | [43] |
| miR-1290 and miR-375 | Plasma exosomes derived from CRPC patients with different prognosis | [44] |
| miR-130b and Met     | Serum exosomes isolated from prostate cancer patients and healthy donors | [45] |
| circPRMT5            | Serum and urine exosomes from normal people and patients with UCB | [46] |
| Exosomal proteins    |                     |      |
| CD82                 | Exosomes derived from tissue, serum, and plasma in breast cancer patients | [47] |
| Eps8                 | Exosomes purified from human pancreatic cancer cell lines with distinct stages | [48] |
| CXCR7 and CXCL12     | Exosomes isolated from tissues of primary tumor, lung metastasis, and benign lung disease in CRC patients | [49] |

Note: Patient-derived liver cell, PDLC; Hepatocellular carcinoma, HCC; Castration-resistant prostate cancer, CRPC; Urothelial carcinoma of the bladder, UCB; Colorectal cancer, CRC.

To demonstrate this hypothesis, it might be necessary to monitor exosomes alteration in blood of patients without detectable metastasis and then conduct long-term tracking of exosomal biomarkers for patients after tumor resection.

(b) What Causes the Difference of Exosomal Biomarker Levels in Serum and Plasma? Exosomal CD82 content in serum is different from that in plasma. Serum exosomal CD82 content in the malignant group is higher than that in the benign group and in the healthy group. However, the content difference between the above groups for plasma exosomes has no statistical significance; therefore serum exosome CD82 is proposed as the biomarker for breast cancer [47].

The study reminds us that detection of exosomal biomarkers in blood is dependent on selection of an appropriate specimen. Serum or plasma may give differing diagnostic test values. We need to further investigate the origin of these observed differences for a better prognosis monitoring.

(c) What Are the Mechanisms Governing the Specific Exosomal Cargo Targeting between Tumor- and Recipient Cells Which Contribute to Inconsistent Expression of Exosomal Inclusions in Blood and Tissue? The levels of miR-486-5p are downregulated in CRC tissue while upregulated in plasma of patients [56]. Therefore, we can postulate that redistribution of miR-485-5p from tissues to exosomes gives rise to partial expression difference between tissue and blood. Low levels of miR-486-5p in tumor cells might consequently influence cell function.

Under the above speculation, exosomes are putative molecular transporters modifying their levels both in tumor cells and in recipient cells. They further alter the state of the two kinds of cells, being either beneficial or obstructive for laboratories. Therefore, more standard and specific isolation and characterization methods are required for exosomes, in order to be suitable for clinical application. We refer the readers to a recent review including methodological classification, detection principle, and new technological methods for analyzing EVs [52].

Moreover, microvesicles as one of the EV types also gave rise to much attention in the cancer field. The prostate cancer cells-derived large oncosomes (a new class of shedded vesicles) are endocytosed by fibroblasts, which activates Myc proto-oncogene protein (MYC) of recipient cells via active AKT1, giving these fibroblasts a protumor phenotype [53]. Bertolini et al. have demonstrated that glioma stem cells-derived large oncosomes deliver homeobox genes and V-ATPase subunit to tumor cells and nontumor cells, which facilitates their malignant transformation [54, 55]. Therefore, the intricate identities and functions of the different EVs warrant further investigation.

3. Open Questions about the Influence of Exosomes on Metastasis

(a) Are Exosomes Still Playing a Role during Tumor Latency or after Primary Tumor Resection? During tumor latency, there are both quiescent single cells and micrometastasis. Duration of the dormant state differs in different cancers [5]. It has been well documented that metastasis sometimes still occurs after primary tumor resection.

A further question arises as to what stimulates these dormant cells into active states and promotes metastasis without a primary tumor. The contributor may be partially remaining exosomes derived from these seemingly stationary tumor cells in predetermined metastasis sites.
tumor progression. Deciphering this important question is only in its infancy.

4. Conclusion

It can be expected that more specific therapeutic targets for cancer metastasis will be developed following these studies. Some research has already demonstrated that tumor cells are inhibited by reducing the production of some exosomes, by interfering with their encapsulated content before or after its packaging, as well as by modifying exosomes as drug carriers [57, 58].

Abbreviations

List 1 (Abbreviations of Cancer Cells, Microenvironment Cells, Cell Components, Organs, and Biological Processes)

- BMDC: Bone marrow-derived cell
- BM-MSC: Bone marrow-mesenchymal stem cell
- CAF: Cancer-associated fibroblast
- CRC: Colorectal cancer
- CRPC: Castration-resistant prostate cancer
- CSC: Cancer stem cell
- CSCC: Cervical squamous cell carcinoma
- ECM: Extracellular matrix
- EMT: Epithelial-mesenchymal transition
- EOC: Epithelial ovarian cancer
- EV: Extracellular vesicle
- HCC: Hepatocellular carcinoma
- HLEC: Human lymphatic endothelial cell
- HNSCC: Head and neck squamous cell carcinoma
- HUVEC: Human umbilical vein endothelial cell
- LAC: Lung adenocarcinoma cell
- LLC: Lewis lung carcinoma
- LN: Lymph node
- MET: Mesenchymal-epithelial transition
- MSC: Mesenchymal stem cell
- OSCC: Oral squamous cell carcinoma
- PDAC: Pancreatic ductal adenocarcinoma
- PDLC: Patient-derived liver cell
- TAM: Tumor associated macrophage
- Th17: Helper T cell 17
- Treg: Regulatory T cell

List 2 (Abbreviations of Different Molecular Components)

- AKT: Serine/threonine-protein kinase Akt
- ANXA1: Annexin A1
- ANXA6: Annexin A6
- AXL: Tyrosine-protein kinase receptor AXL
- Bax: Apoptosis regulator BAX
- Bcl2: Apoptosis regulator Bcl-2
- bFGF: Basic fibroblast growth factor
- BRG1: Transcription activator BRG1
- CAV1: Caveolin-1
- CCL2: C-C motif chemokine ligand 2
- CCR2+: C-C chemokine receptor type 2 positive
- CD82: CD82 antigen
- CircPRMT5: Protein arginine N-methyltransferase 5 circular RNA
- CRISPR/Cas9: Clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9
- CXCL12: C-X-C motif chemokine ligand 12
- CXCR7: C-X-C chemokine receptor type 7
- DEN: Diethylaminoethylamine
- DUSP14: Dual specificity protein phosphatase 14
- ENA-78: Epithelial-derived neutrophil-activating protein 78
- Eps8: Epidermal growth factor receptor pathway substrate 8
- ERK: Extracellular signal-regulated kinase
- FAK: Focal adhesion kinase
- GSK-3β: Glycogen synthase kinase-3 beta
- HIF1A: Hypoxia-inducible factor 1-alpha
- IL: Interleukin
- ITG: Integrin
- KLF: Kruppel-like factor
- KNOX1: Kupffer cell nuclear antigen
- lnc-MMP2-2: Lnc-matrix metalloproteinase 2-2
- lncRNA-ATB: LncRNA-activated by tumor growth factor-beta
- Ly6C+: Lymphocyte antigen 6C positive
- MALAT1: Metastasis-associated lung adenocarcinoma transcript 1
- MAPK: Mitogen-activated protein kinase
- Met: Tyrosine-protein kinase Met or Hepatocyte growth factor receptor
- MIF: Migration inhibitory factor
- MMP: Matrix metalloproteinase
- MMP2: Matrix metalloproteinase 2
- MYC: Myc proto-oncogene protein
- NF-kB: Nuclear factor kappa-light-chain-enhancer of activated B cells
- p27: Cyclin-dependent kinase inhibitor 1B (p27kip1)
- p53: Cellular tumor antigen p53
- PI3K: Phosphoinositide 3-kinase
- PIGF: Placental growth factor
- PPP2R2A: Serine/threonine-protein phosphatase 2A
- PTEN: Phosphatase and tensin homolog
- RAB27A: Ras-related protein Rab-27A
- S100: A family of genes whose symbols use the S100 prefix; the “S100” symbol prefix is derived from the fact that these proteins are soluble in 100% ammonium sulfate at neutral pH
- S100A: S100 calcium-binding protein A
- SNAIL: Zinc finger transcription factor SNAIL
- snRNA: Small nuclear RNA
- Src: Proto-oncogene tyrosine-protein kinase Src
- STAT3: Signal transducer and activator of transcription 3
- TGFβ: Transforming growth factor beta
TIMP1: Tissue inhibitor of metalloproteinases  
TLR: Toll-like receptor  
VASH1: Vasohibin-1  
VEGF: Vascular endothelial growth factor  
Wnt4: Protein Wnt-4.

Additional Points

MIA PaCa-2. The cell line was established by A. Yunis et al. in 1975 from tumor tissue of the pancreas obtained from a 65-year-old Caucasian male. The information is obtained via ATCC website (https://www.atcc.org/). Tumor Associated M2 Macrophage. Macrophages generally consist of the two types: M1- and M2 macrophages. Studies have shown that M2 macrophages are more likely to promote tumor progression.

Conflicts of Interest

The authors declare no conflicts of interest

Acknowledgments

The authors thank Quinn Ellner for English editing. This work was supported by grants from the provincial key scientific and technological project (project number: 2014K11-01-01-20).

Supplementary Materials

Table S1: Difference among the three main types of EVs. (Supplementary Materials)

References

[1] American Cancer Society, Global Cancer Facts & Figures, American Cancer Society, Atlanta, GA, USA, 4th edition, 2018.
[2] P. S. Steeg, “Targeting metastasis,” Nature Reviews Cancer, vol. 16, no. 4, pp. 201–218, 2016.
[3] R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2019,” CA: A Cancer Journal for Clinicians, vol. 69, no. 1, pp. 7–34, 2019.
[4] R. L. Anderson, T. Balasas, J. Callaghan et al., “A framework for the development of effective anti-metastatic agents,” Nature Reviews Clinical Oncology, vol. 16, no. 3, pp. 183–204, 2019.
[5] M. Akhtar, A. Haider, S. Rashid, and A. Al-Nabat, “Paget’s ‘Seed and Soil’ Theory of Cancer Metastasis: An Idea Whose Time has Come,” (1533–4031 (Electronic)).
[6] H. Peinado, H. Zhang, I. R. Matei et al., “Pre-metastatic niches: organ-specific homes for metastases,” Nature Reviews Cancer, vol. 17, no. 5, pp. 302–317, 2017.
[7] Y. Liu and X. Cao, “Characteristics and Significance of the Pre-metastatic Niche,” Cancer Cell, vol. 30, no. 5, pp. 668–681, 2016.
[8] G. Van Niel, G. D’Angelo, and G. Raposo, “Shedding light on the cell biology of extracellular vesicles,” Nature Reviews Molecular Cell Biology, vol. 19, no. 4, pp. 213–228, 2018.
[9] M. Yanez-Mo, P. R. Siljander, and Z. Andreu, “Biological properties of extracellular vesicles and their physiological functions,” Journal of Extracellular Vesicles (JEV), vol. 4, Article ID 27066, 2015.
[10] V. Budnik, C. Ruiz-Cañada, and F. Wendler, “Extracellular vesicles round off communication in the nervous system,” Nature Reviews Neuroscience, vol. 17, no. 3, pp. 160–172, 2016.
[11] M. Colombo, G. Raposo, and C. Théry, “Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles,” Annual Review of Cell and Developmental Biology, vol. 30, no. 1, pp. 255–289, 2014.
[12] M. Qu, Q. Lin, L. Huang et al., “Dopamine-loaded blood exosomes targeted to brain for better treatment of Parkinson’s disease,” Journal of Controlled Release, vol. 287, pp. 156–166, 2018.
[13] G. Raposo and W. Stoorvogel, “Extracellular vesicles: exosomes, microvesicles, and friends,” The Journal of Cell Biology, vol. 200, no. 4, pp. 373–383, 2013.
[14] S. El Andaloussi, I. Mäger, X. O. Breakefield, and M. J. A. Wood, “Extracellular vesicles: biology and emerging therapeutic opportunities,” Nature Reviews Drug Discovery, vol. 12, no. 5, pp. 347–357, 2013.
[15] C. Théry, L. Zitvogel, and S. Amigorena, “Exosomes: composition, biogenesis and function,” Nature Reviews Immunology, vol. 2, no. 8, pp. 569–579, 2002.
[16] A. Hoshino, B. Costa-Silva, TL. Shen, G. Rodrigues, A. Hashimoto, M. Tesic Mark et al., “Tumour exosome integrins determine organotropic metastasis,” Nature, vol. 527, pp. 329–335, 2015.
[17] B. Costa-Silva, N. M. Aiello, and A. J. Oean, “Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver,” Nature Cell Biology, vol. 17, no. 6, pp. 816–826, 2015.
[18] Z. Wan, X. Gao, Y. Dong, Y. Zhao, X. Chen, G. Yang et al., “Exosome-mediated cell-cell communication in tumor progression,” (2156-6976 (Print)).
[19] Y. Liu, Y. Gu, Y. Han et al., “Tumor Exosomal RNAs Promote Lung Pre-metastatic Niche Formation by Activating Alveolar Epithelial TLR3 to Recruit Neutrophils,” Cancer Cell, vol. 30, no. 2, pp. 243–256, 2016.
[20] D. Löffler, K. Brocke-Heidrich, G. Pfeifer et al., “Interleukin-6-dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer,” Blood, vol. 110, no. 4, pp. 1330–1333, 2007.
[21] Y. Shao, T. Chen, X. Zheng, S. Yang, K. Xu, X. Chen et al., “Colonrectal cancer-derived small extracellular vesicles establish an inflammatory premetastatic niche in liver metastasis,” Carcinogenesis, vol. 39, no. 11, pp. 1368–1379, 2018.
[22] J. Qu, X. Lin, X. Tang, T. Zheng, Y. Lin, and K. Hua, “Exosomal Metastasis-Associated Lung Adenocarcinoma Transcript 1 Promotes Angiogenesis and Predicts Poor Prognosis in Epithelial Ovarian Cancer,” International Journal of Biological Sciences, vol. 14, no. 14, pp. 1960–1973, 2018.
[23] Z. Zeng, Y. Li, Y. Pan et al., “Cancer-derived exosomal miR-25-3p promotes pre-metastatic niche formation by inducing vascular permeability and angiogenesis,” Nature Communications, vol. 9, no. 1, 2018.
[24] E. Pessolano, R. Belvedere, V. Bizzarro et al., “Annexin A1 May Induce Pancreatic Cancer Progression as a Key Player of Extracellular Vesicles Effects as Evidenced in the In Vitro MIA PaCa-2 Model System,” International Journal of Molecular Sciences, vol. 19, no. 12, p. 3878, 2018.
[25] C. Zhou, J. Ma, L. Huang et al., “Cervical squamous cell carcinoma-secreted exosomal miR-221-3p promotes lymphangiogenesis and lymphatic metastasis by targeting VASH1,” Oncogene, vol. 38, no. 8, pp. 1256–1268, 2019.
[26] J. Lawson, C. Dickman, R. Towle, J. Jabalee, A. Javer, and C. Garnis, “Extracellular vesicle secretion of miR-142-3p from lung adenocarcinoma cells induces tumor promoting changes in the stroma through cell-cell communication,” Molecular Carcinogenesis, vol. 58, no. 3, pp. 376–387, 2019.

[27] J. Wang, X. Guan, Y. Zhang et al., “Exosomal miR-27a Derived from Gastric Cancer Cells Regulates the Transformation of Fibroblasts into Cancer-Associated Fibroblasts,” Cellular Physiology and Biochemistry, vol. 49, no. 3, pp. 869–883, 2018.

[28] M. Madeo, P. L. Colbert, D. W. Vermeer, C. T. Lucido, J. T. Cain, E. G. Vichaya et al., “Cancer exosomes induce tumor innervation,” Nature Communications, vol. 9, no. 1, p. 4284, 2018.

[29] J. Zhou, X. Li, X. Wu et al., “Exosomes Released from Tumor-Associated Macrophages Transfer miRNAs That Induce a Treg/Th17 Cell Imbalance in Epithelial Ovarian Cancer,” Cancer Immunology Research, vol. 6, no. 12, pp. 1578–1592, 2018.

[30] S. Shojaei, S. M. Hashemi, H. Ghanbarian, M. Salehi, and J. Lawson, C. Dickman, R. Towle, J. Jabalee, A. Javer, and J. Lawson, “Cancer exosomes induce tumor innervation,” Nature Communications, vol. 9, no. 1, p. 4284, 2018.

[31] Z. Li, Y. Tao, X. Wang et al., “TGF-β-mediated exosomal Inc-MMP2-2 regulates migration and invasion of lung cancer cells to the vasculature by promoting MMP2 expression,” Cancer Medicine, vol. 7, no. 10, pp. 5118–5129, 2018.

[32] D. Guo, G. Y. L. Lui, S. L. Lai, J. S. Wilmott, S. Tikoo, L. A. Jackett et al., “RAB27A promotes melanoma cell invasion and metastasis via regulation of pro-invasive exosomes,” International Journal of Cancer, vol. 144, no. 12, Article ID 30556600, pp. 3070–3085, 2018.

[33] D. Wu, S. Deng, T. Liu, R. Han, T. Zhang, and Y. Xu, “TGFβ-mediated exosomal Inc-MMP2-2 regulates migration and invasion of lung cancer cells to the vasculature by promoting MMP2 expression,” Cancer Medicine, vol. 7, no. 10, pp. 5118–5129, 2018.

[34] Z. Huang, M. Yang, Y. Li, F. Yang, and Y. Feng, “Exosomes Derived from Hypoxic Colorectal Cancer Cells Transfer Wnt4 to Normoxic Cells to Elicit a Prometastatic Phenotype,” International Journal of Biological Sciences, vol. 14, no. 14, pp. 2094–2102, 2018.

[35] Z. Li, Y. Tao, X. Wang et al., “Tumor-Secreted Exosomal miR-222 Promotes Tumor Progression via Regulating P27 Expression and Re-Localization in Pancreatic Cancer,” Cellular Physiology and Biochemistry, vol. 51, no. 2, pp. 601–629, 2018.

[36] A. Campos, C. Salomon, R. Bustos et al., “Caveolin-1-containing extracellular vesicles transport adhesion proteins and promote malignancy in breast cancer cell lines,” Nanomedicine, vol. 13, no. 20, pp. 2597–2609, 2018.

[37] T. Shtam, S. Naryzhny, R. Samsonov et al., “Plasma exosomes stimulate breast cancer metastasis through surface interactions and activation of FAK signaling,” Breast Cancer Research and Treatment, vol. 174, no. 1, pp. 129–141, 2019.

[38] J. Lan, L. Sun, F. Xu et al., “M2 Macrophage-Derived Exosomes Promote Cell Migration and Invasion in Colon Cancer,” Cancer Research, vol. 79, no. 1, pp. 146–150, 2019.

[39] Y.-Y. Li, Y.-W. Tao, S. Gao et al., “Cancer-associated fibroblasts contribute to oral cancer cells proliferation and metastasis via exososome-mediated paracrine miR-34a-5p,” EBioMedicine, vol. 36, pp. 209–220, 2018.

[40] F. A. Alzahrani, M. A. El-Magd, A. Abdelfattah-Hassan et al., “Potential Effect of Exosomes Derived from Cancer Stem Cells and MSCs on Progression of DEN-Induced HCC in Rats,” Stem Cells International, vol. 2018, pp. 1–17, 2018.

[41] L. Yu, B. Zhang, Y. Yang et al., “Exosomal microRNAs as potential biomarkers for cancer cell migration and prognosis in hepatocellular carcinoma patient-derived cell models,” Oncology Reports, vol. 41, no. 1, pp. 257–269, 2018.

[42] Y. R. Lee, G. Kim, W. Y. Tak et al., “Circulating exosomal noncoding RNAs as prognostic biomarkers in human hepatocellular carcinoma,” International Journal of Cancer, vol. 144, no. 6, pp. 1444–1452, 2019.

[43] V. kia, M. Paryan, Y. Mortazavi, A. Biglari, and S. Mohammadi-Yeganeh, “Evaluation of exosomal miR-9 and miR-155 targeting PTEN and DUSP14 in highly metastatic breast cancer and their effect on low metastatic cells,” Journal of Cellular Biochemistry, 2018.

[44] X. Huang, T. Yuan, M. Liang et al., “Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer,” European Urology, vol. 67, pp. 33–41, 2014.

[45] A. Cannistraci, G. Federici, A. Addario et al., “C-Met/MIR-130b axis as novel mechanism and biomarker for castration resistance state acquisition,” Oncogene, vol. 36, no. 26, pp. 3718–3728, 2017.

[46] X. Chen, R. Shen, W. Wei et al., “PRMT5 Circular RNA Promotes Metastasis of Urothelial Carcinoma of the Bladder through Sponging miR-30c to Induce Epithelial–Mesenchymal Transition,” Clinical Cancer Research, vol. 24, no. 24, pp. 6319–6330, 2018.

[47] X. Wang, W. Zhong, J. Bu et al., “Exosomal protein CD82 as a diagnostic biomarker for precision medicine for breast cancer,” Molecular Carcinogenesis, vol. 58, no. 5, pp. 674–685, 2019.

[48] K. Ohshima, K. Hatakeyama, K. Kanto et al., “Comparative proteomic analysis identifies exosomal Epbs protein as a potential metastatic biomarker for pancreatic cancer,” Oncology Reports, vol. 41, no. 2, pp. 1019–1034, 2018.

[49] M. Wang, X. Yang, M. Wei, and Z. Wang, “The Role of CXCL12 Axis in Lung Metastasis of Colorectal Cancer,” Journal of Cancer, vol. 9, no. 21, pp. 3898–3903, 2018.

[50] Z. Zhu, H. Shen, X. Yin et al., “Macrophages derived exosomes deliver miR-223 to epithelial ovarian cancer cells to elicit a chemoresistant phenotype,” Journal of Experimental & Clinical Cancer Research, vol. 38, no. 1, 2019.

[51] I. Keklikoglou, C. Cianciariuso, E. Giç et al., “Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models,” Nature Cell Biology, vol. 21, no. 2, pp. 190–202, 2019.

[52] H. Shao, H. Im, C. M. Castro, X. Breakefield, R. Weissleder, and H. Lee, “New Technologies for Analysis of Extracellular Vesicles,” Chemical Reviews, vol. 118, no. 4, pp. 1917–1950, 2018.

[53] V. R. Minciacchi, C. Spinelli, M. Reis-Sobreiro et al., “MYC mediates large oncosome-induced fibroblast reprogramming in prostate cancer,” Cancer Research, vol. 77, no. 9, pp. 2306–2317, 2017.

[54] I. Bertolini, A. Terrasi, C. Martelli et al., “A GBM-like V-ATPase signature directs cell-cell tumor signaling and reprogramming via large oncosomes,” EBioMedicine, vol. 41, pp. 225–235, 2019.

[55] D. Garnier, “Reprogramming of GBM microenvironment by large oncosomes: ‘Traveling’ V-ATPases are doing more than acidification,” EBioMedicine, vol. 41, pp. 15-16, 2019.

[56] X. Liu, X. Chen, K. Zeng et al., “DNA-methylation-mediated silencing of miR-486-5p promotes colorectal cancer proliferation and migration through activation of PLAGL2/IGF2/F- catenin signal pathways,” Cell Death & Disease, vol. 9, no. 10, p. 1037, 2018.
[57] H. Zheng, Y. Zhan, S. Liu et al., “The roles of tumor-derived exosomes in non-small cell lung cancer and their clinical implications,” *Journal of Experimental & Clinical Cancer Research*, vol. 37, no. 1, 2018.

[58] D. Kyuno, K. Zhao, N. Bauer, E. Ryschich, and M. Zöller, “Therapeutic Targeting Cancer-Initiating Cell Markers by Exosome miRNA: Efficacy and Functional Consequences Exemplified for claudin7 and EpCAM,” *Translational Oncology*, vol. 12, no. 2, pp. 191–199, 2019.